Answers are grounded in this paper and cite their sources.
Cross-sectional analysis finds METS-VF predicts gallstones in adults, suggesting improved screening methods.
Background and Aims Obesity is a well-established risk factor for gallstone formation, but traditional anthropometric measures (e.g., BMI, waist circumference) inadequately assess metabolically active visceral adiposity. The novel Metabolic Score for Visceral Fat (METS-VF) may better capture obesity-related metabolic dysfunction. We aimed to investigate the association between METS-VF and gallstone prevalence and compare its predictive performance against conventional obesity indices (WC, LAP, VAI) in a U.S. national cohort. Methods This cross-sectional study analyzed nationally representative data from 3,010 US adults in NHANES 2017–2020 (aged 20–85 years, 51.3% male, multi-ethnic population). We employed weighted multivariable logistic regression to examine the METS-VF-gallstones association, with restricted cubic splines testing nonlinearity. Predictive performance of METS-VF versus traditional indices (WC/LAP/VAI) was compared using ROC curves and XGBoost machine learning. Results Among 3,010 U.S. adults (mean age 47.8 ± 17.0 years, 51.3% male) in the NHANES 2017–2020 cohort, multivariable analysis revealed METS-VF as the strongest independent predictor of gallstones (adjusted OR = 2.02, 95%CI:1.20–3.40). Notably, METS-VF demonstrated significantly superior discriminative ability with the highest AUC of 0.712 (95%CI:0.684–0.739) compared to conventional indices (WC:0.635, LAP:0.609, VAI:0.530; all P < 0.05). Conclusion The cross-sectional analysis demonstrates a significant association between METS-VF and gallstone prevalence (OR = 2.02, 95% CI:1.20–3.40), with relatively better predictive performance compared to conventional adiposity indices (AUC = 0.712). Its simple calculation using routine clinical measurements makes it ideally suited for implementation in primary care screening programs targeting high-risk populations with visceral adiposity. While these findings position METS-VF as a promising screening marker, its etiological role requires verification through longitudinal studies.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: